In this phase 2 study , we evaluated the effect of letermovir ( also known as AIC246 ) , a new anti-CMV drug with a novel mechanism of action , on the incidence and time to onset of prophylaxis failure in CMV-seropositive recipients of allogeneic hematopoietic-cell transplants from matched related or unrelated donors .